Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Gray matter magnetic resonance imaging T2 hypointensity, a marker of iron deposition, is associated with clinical impairment and brain atrophy in cross-sectional studies of multiple sclerosis. Treatment with intramuscular interferon beta-1a limits brain atrophy in the second year of treatment. OBJECTIVE: To test whether T2 hypointensity predicts brain atrophy and whether interferon affects this relationship. DESIGN: Post hoc analysis. SETTING: A multicenter treatment trial conducted at tertiary care comprehensive multiple sclerosis centers. Patients Patients with multiple sclerosis who took part in a 2-year clinical trial in which they received intramuscular interferon beta-1a (30 mug/wk) or placebo. MAIN OUTCOME MEASURES: Deep gray matter T2 hypointensity, brain parenchymal fraction (BPF), and total T2, gadolinium-enhancing, and T1 lesion volumes. RESULTS: T2 hypointensity in various gray matter areas correlated with baseline BPF (r = 0.19-0.39; P = .001-.03). In placebo-treated patients (n = 68), baseline T2 hypointensity predicted the change in BPF in the first year and throughout 2 years (r = 0.26-0.42; P<.001-.03). T2 hypointensity was chosen in regression modeling as the best predictor of BPF change at the 1-year (R(2) = 0.23; P = .002) and 2-year (R(2) = 0.33; P<.001) time points after accounting for all magnetic resonance imaging variables. In the interferon group (n = 65), no relationship existed between baseline T2 hypointensity and BPF change. CONCLUSIONS: Gray matter T2 hypointensity predicts the progression of brain atrophy in placebo- but not interferon beta-1a-treated patients. This predictive effect is seen as early as the first year. We hypothesize that interferon beta may exert its effect on brain atrophy in part by reducing a cascade of events that involve iron deposition as a mediator of neurotoxicity or as a disease epiphenomenon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationCortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766
Perivascular iron deposition and other vascular damage in multiple sclerosis.
Adams, C. W. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.2.260 · Cited by 178
Mehindate, K., Sahlas, D. J., Frankel, D., Mawal, Y., Liberman, A., Corcos, J., Dion, S., & Schipper, H. M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00354.x · Cited by 129 · cited 9×
“31 Emerging data implicate abnormal iron metabolism as one of the pathophysiologic mechanisms of MS. 33,36,37,45 Ferritin levels are elevated in patients with chronic progressive MS. 37 Heme oxygenase 1 is upregulated and is related to increased tissue iron in MS.”
BackgroundInfluentialBakshi, R., Dmochowski, J., Shaikh, Z. A., & Jacobs, L. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00477-4 · Cited by 107
Self-citationMRI T2 shortening (‘black T2’) in multiple sclerosis: frequency, location, and clinical correlation
Bakshi, R., Shaikh, Z. A., & Janardhan, V. (2000) · NeuroReport · doi:10.1097/00001756-200001170-00004 · Cited by 92 · cited 1×
“Another limitation was that clinical correlations were not investigated; however, previous work has linked T2 hypointensity of deep gray matter to physical disability and disease course.(27,28) Rudick et al(51) examined this cohort for effects of corticosteroid treatment and found no effect on the rate of atrophy.”
BackgroundSelf-citation
Cited by
Thalamic atrophy and cognition in multiple sclerosis
Houtchens, M. K., Benedict, R. H. B., Killiany, R., Sharma, J., Jaisani, Z., Singh, B., Weinstock-Guttman, B., Guttmann, C. R. G., & Bakshi, R. (2007) · Neurology · doi:10.1212/01.wnl.0000276992.17011.b5 · Cited by 496
Self-citationThe measurement and clinical relevance of brain atrophy in multiple sclerosis
Bermel, R. A., & Bakshi, R. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70349-0 · Cited by 456
Self-citationKell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Gray matter involvement in multiple sclerosis
Pirko, I., Lucchinetti, C. F., Sriram, S., & Bakshi, R. (2007) · Neurology · doi:10.1212/01.wnl.0000250267.85698.7a · Cited by 349
Self-citationMRI in multiple sclerosis: current status and future prospects
Bakshi, R., Thompson, A. J., Rocca, M. A., Pelletier, D., Dousset, V., Barkhof, F., Inglese, M., Guttmann, C. R., Horsfield, M. A., & Filippi, M. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70137-6 · Cited by 348
Self-citation
Metadata
- Authors
- Bermel, R. A., Puli, S. R., Rudick, R. A., Weinstock-Guttman, B., Fisher, E., Munschauer, F. E., & Bakshi, R.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2005-09-01
- Volume
- 62
- Issue
- 9
- Pages
- 1371
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2152276235
- Cited by
- 101
- References
- 6
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.